Pretreatment characteristics of evaluable patients
| Characteristic . | APML4 . | APML3 . | P (APML4 vs APML3) . | ||
|---|---|---|---|---|---|
| n (%) . | Median (range) . | n (%) . | Median (range) . | ||
| No. of patients | 124 (100) | 70 (100) | |||
| Age, y | 44 (3-78) | 39 (19-73) | .06 | ||
| Age subgroup, y | |||||
| ≤ 60 | 108 (87) | 63 (90) | |||
| 61-70 | 9 (7) | 6 (9) | .43 | ||
| > 70 | 7 (6) | 1 (1) | |||
| Sex | |||||
| Male | 62 (50) | 37 (53) | .77 | ||
| Female | 62 (50) | 33 (47) | |||
| ECOG status | |||||
| 0 | 64 (52) | 37 (53) | |||
| 1 | 43 (35) | 23 (33) | .57 | ||
| 2 | 11 (9) | 9 (13) | |||
| 3 | 6 (5) | 1 (1) | |||
| FAB classification* | |||||
| M3 | 99 (80) | 57 (81) | .85 | ||
| M3v | 25 (20) | 13 (19) | |||
| PML breakpoint† | |||||
| bcr1 | 66 (53) | 38 (57) | |||
| bcr2 | 8 (6) | 6 (9) | .64 | ||
| bcr3 | 50 (40) | 23 (34) | |||
| WBC count, × 109/L | 2.4 (0.1-85.8) | 2.4 (0.4-109.0) | .99 | ||
| Platelet count, × 109/L‡ | 22 (1-173) | 22 (4-180) | .61 | ||
| Sanz risk category‡ | |||||
| Low | 32 (26) | 20 (29) | |||
| Intermediate | 67 (54) | 35 (50) | .85 | ||
| High | 24 (20) | 15 (21) | |||
| FLT3 status§ | |||||
| Wild-type | 66 (56) | 37 (59) | .75 | ||
| Mutation | 52 (44) | 26 (41) | |||
| Characteristic . | APML4 . | APML3 . | P (APML4 vs APML3) . | ||
|---|---|---|---|---|---|
| n (%) . | Median (range) . | n (%) . | Median (range) . | ||
| No. of patients | 124 (100) | 70 (100) | |||
| Age, y | 44 (3-78) | 39 (19-73) | .06 | ||
| Age subgroup, y | |||||
| ≤ 60 | 108 (87) | 63 (90) | |||
| 61-70 | 9 (7) | 6 (9) | .43 | ||
| > 70 | 7 (6) | 1 (1) | |||
| Sex | |||||
| Male | 62 (50) | 37 (53) | .77 | ||
| Female | 62 (50) | 33 (47) | |||
| ECOG status | |||||
| 0 | 64 (52) | 37 (53) | |||
| 1 | 43 (35) | 23 (33) | .57 | ||
| 2 | 11 (9) | 9 (13) | |||
| 3 | 6 (5) | 1 (1) | |||
| FAB classification* | |||||
| M3 | 99 (80) | 57 (81) | .85 | ||
| M3v | 25 (20) | 13 (19) | |||
| PML breakpoint† | |||||
| bcr1 | 66 (53) | 38 (57) | |||
| bcr2 | 8 (6) | 6 (9) | .64 | ||
| bcr3 | 50 (40) | 23 (34) | |||
| WBC count, × 109/L | 2.4 (0.1-85.8) | 2.4 (0.4-109.0) | .99 | ||
| Platelet count, × 109/L‡ | 22 (1-173) | 22 (4-180) | .61 | ||
| Sanz risk category‡ | |||||
| Low | 32 (26) | 20 (29) | |||
| Intermediate | 67 (54) | 35 (50) | .85 | ||
| High | 24 (20) | 15 (21) | |||
| FLT3 status§ | |||||
| Wild-type | 66 (56) | 37 (59) | .75 | ||
| Mutation | 52 (44) | 26 (41) | |||
French-American-British.
PML breakpoint was not available in 3 APML3 patients, so n = 67.
Pretransfusion platelet count was not available in 1 APML4 patient, so n = 123.
FLT3 status was available for 118 APML4 patients (95%) and 63 APML3 patients (90%); FLT3 mutations included ITDs and/or codon 835/836 mutations.